Figure 1.
Tissue microarray based representative immunohistochemical analysis of MYC protein expression in DLBCL.
The MYC staining pattern is distinctly nuclear. (A, C) DLBCL scored as having ≥40% MYC-positive lymphoma cells. (B, D) DLBCL scored as having <40% MYC-positive lymphoma cells. A and B original magnification, ×40. C and D original magnification, ×400.
Table 1.
Clinical and immunophenotypical characteristics of DLBCL, NOS patients.
Table 2.
Patient clinical and immunophenotypical characteristics of patients with DLBCL, NOS in relation to protein expressions.
Table 3.
Patient clinical and immunophenotypical characteristics of patients with DLBCL, NOS in relation to DHS and THS.
Figure 2.
Prognostic impact of MYC, BCL2, BCL6 and Ki67 expression in DLBCL patients treated with CHOP.
Patients’ tumors were stained for (A, B) MYC, (C, D) BCL2, (E, F) BCL6, and (G, H) Ki67. The numbers of patients showing negative or positive stainings (MYC≥40%, BCL2≥70%, BCL6≥50%, Ki67≥90%), cut-off values, and P values are indicated.
Figure 3.
Prognostic impact of MYC, BCL2, BCL6 and Ki67 expression in DLBCL patients treated with R-CHOP.
Patients’ tumors were stained for (A, B) MYC, (C, D) BCL2, (E, F) BCL6, and (G, H) Ki67. The numbers of patients showing negative or positive stainings (MYC≥40%, BCL2≥70%, BCL6≥50%, Ki67≥90%), cut-off values, and P values are indicated.
Figure 4.
Prognostic impact of DHSs and THS in DLBCL patients treated with CHOP.
(A, B) OS (A) and PFS (B) of patients with MYC/BCL2 DHS. (C, D) OS (C) and PFS (D) of patients with MYC/BCL6 DHS. (E, F) OS (E) and PFS (F) of patients with BCL2/BCL6 DHS. (G, H) OS (G) and PFS (H) of patients with MYC/BCL2/BCL6 THS. OS, overall survival; PFS, progression-free survival; DHS, double-hit score; THS, triple-hit score.
Figure 5.
Prognostic impact of DHSs and THS in DLBCL patients treated with R-CHOP.
(A, B) OS (A) and PFS (B) of patients with MYC/BCL2 DHS. (C, D) OS (C) and PFS (D) of patients with MYC/BCL6 DHS. (E, F) OS (E) and PFS (F) of patients with BCL2/BCL6 DHS. (G, H) OS (G) and PFS (H) of patients with MYC/BCL2/BCL6 THS. OS, overall survival; PFS, progression-free survival; DHS, double-hit score; THS, triple-hit score.
Table 4.
Univariate Cox models for DLBCL, NOS patients treated with CHOP.
Table 5.
Univariate Cox models for DLBCL, NOS patients treated with R-CHOP.
Table 6.
Multivariate Cox models for DBCL, NOS patients treated with CHOP (n = 203).
Table 7.
Multivariate Cox models for DBCL, NOS patients treated with R-CHOP (n = 118).
Figure 6.
Prognostic impact of treatments in DLBCL risk-stratified according to immunohistochemical subgroups.
(A, B) OS (A) and PFS (B) of all patients treated with CHOP or R-CHOP. (C, D) OS (C) and PFS (D) of patients treated with CHOP or R-CHOP in GCB subgroup. (E, F) OS (E) and PFS (F) of patients treated with CHOP or R-CHOP in non-GCB subgroup. OS, overall survival; PFS, progression-free survival; GCB, germinal center B-cell.
Figure 7.
Prognostic impact of immunohistochemical subtypes in DLBCL risk-stratified according to treatments.
(A, B) OS (A) and PFS (B) of all patients with GCB subtype or non-GCB subtype. (C, D) OS (C) and PFS (D) of CHOP-treated patients with GCB subtype or non-GCB subtype. (E, F) OS (E) and PFS (F) of R-CHOP-treated patients with GCB subtype or non-GCB subtype. OS, overall survival; PFS, progression-free survival; GCB, germinal center B-cell.
Figure 8.
Prognostic impact of IPI in DLBCL risk-stratified according to treatments.
(A, B) OS (A) and PFS (B) of all patients with IPI 0–2 or IPI 3–5. (C, D) OS (C) and PFS (D) of CHOP-treated patients with IPI 0–2 or IPI 3–5. (E, F) OS (E) and PFS (F) of R-CHOP-treated patients with IPI 0–2 or IPI 3–5. OS, overall survival; PFS, progression-free survival; IPI, International Prognostic Index.